Ocriplasmin receives NICE recommendation for treatment of vitreomacular traction

Article

The National Institute for Health and Care Excellence (NICE) has recommended ocriplasmin (Jetrea) as a clinically effective and cost-effective treatment option for patients suffering from vitreomacular traction, including that associated with macular hole of ? 400 ?m when an epiretinal membrane is absent, or adults with vitreomacular traction and severe symptoms, when an epiretinal membrane and macular hole are both absent.

Basel, Switzerland-The National Institute for Health and Care Excellence (NICE) has recommended ocriplasmin (Jetrea, Novartis/Alcon) as a clinically effective and cost-effective treatment option for patients suffering from vitreomacular traction, including that associated with macular hole of ≤ 400 μm when an epiretinal membrane is absent, or adults with vitreomacular traction and severe symptoms, when an epiretinal membrane and macular hole are both absent.

Vitreomacular traction and macular hole are age-related, and may lead to visual distortion and central blindness. Until the approval of ocriplasmin in March 2013 by the EU commission, treatment of vitreomacular traction involved “watchful waiting,” comprised of a period of patient observation until patients worsened and became eligible for surgical treatment. Surgery was reserved for patients who were heavily impacted by the symptoms of vitreomacular traction due to its potential risks and complications.

With this current recommendation, ocriplasmin, delivered as a single once-only injection to the eye, is recommended for use within the National Health Service (NHS) in England and Wales as the first and only pharmacologic treatment for vitreomacular traction. Clinical trials have shown that within 28 days of injection, about 1 out of 4 patients experience resolution of vitreomacular adhesion. In addition, over 40% of treated patients achieve macular hole closure by day 28.

“People affected by vitreomacular traction can suffer vision changes that have a significant impact on their lives, making it difficult to do everyday activities like reading, watching television, and driving,” said Tim Jackson, retinal surgeon, King’s College Hospital, Denmark Hill, London. “Until now, eye doctors have only had surgical options to treat this disease, once it progressed to a severe stage. This new treatment is a welcome advance, meaning some patients can now avoid surgery, and others who might not be suitable for surgery can now be treated,” he concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.